BioSpace News Archive

Registration Now Open for LA-Area Event Dedicated to Raising Awareness of Neuropathy [18-March-2020] LOS ANGELES , March 18, 2020 /PRNewswire/ -- The Neuropathy Action Foundation (NAF) announced that registration is now open for its 13 th “Neuropathy Action Awareness Day,” an all-day educational event on June 19 in Los Angeles (Note: The NAF will evaluate the cor

Emergent BioSolutions Inc. announced that it has entered into an agreement with Vaxart, Inc., a clinical-stage biotechnology company, whereby Emergent has agreed to utilize its molecule-to-market contract development and manufacturing services to develop and manufacture Vaxart’s experimental oral vaccine candidate for coronavirus disease.

Bio-Techne Corporation announced that the General Services Administration has awarded an unlimited 10-year reimbursement contract to its Exosome Diagnostics laboratory, covering the ExoDx™ Prostate test for men.

IMV Inc., a clinical-stage biopharmaceutical company, announced that it is advancing the clinical development of a DPX-based vaccine candidate against COVID-19.

Meetings with prospective partners regarding Piclidenoson as a potential treatment for coronavirus, in addition to established indications for the Company’s drugs in Phase II and Phase III studies

Revolution Medicines, Inc. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,590,090 providing, in part, composition of matter protection for its SHP2 inhibitors, including RMC-4630. RMC-4630, the company’s investigational SHP2 inhibitor, is a potent and orally bioa

Schizophrenia may find a cure in individualized treatment. So says a new article in the science journal Holistic Nursing Practice

Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, announced changes to the Company’s Executive Leadership Team.

Bristol Myers Squibb Company announced that Elizabeth Mily has been appointed Executive Vice President, Strategy & Business Development, effective March 30, 2020.

Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, announced that the jury verdict in the U.S. District Court for the District of Delaware was not overall favorable for Pacific Biosciences, but mixed in terms of its findings.